Technology
Proteonano™ utilizes proprietary designed polypeptides to selectively bind and enrich low abundant proteins in biofluid samples with high affinities. The diameter of these superparamagnetic nanoparticles is only 200 nm and with absolute homogeneity. Therefore, these features equip these functionalized nanoscale protein binders with approximately 300,000 protein binding sites per particle, which enables them to bind and enrich tens of thousands of proteins in an extremely small space.
The volume around each nanoprobe is only 10 fL, which is 10 billion times smaller than traditional immunological methods. This dramatic
volume reduction elevates the detection sensitivity for low-abundant proteins by one million times.
Thus, low abundant proteins, PTMs, and isoforms that have not been detected b y traditional mass spectrometry before can be seen now. The Proteonano™ technology enables unprecedented depth and throughput in proteome profiling from biofuild samples, making it a powerful tool for discovering large-scale protein biomarkers.
Why we should enrich low-Abundance proteins in plasma?
To detect diseases, including cancer, through blood tests, the first step is to identify disease-related biomarkers. Currently, 100 to 200 plasma proteins have been FDA-approved as disease biomarkers. However, finding biomarkers in blood can be quite challenging.
Studying the human plasma proteome presents significant challenges.
-
It has an extremely wide abundance range, spanning 10 orders of magnitude.
-
Although low-abundance proteins are found in very small amounts, they are extremely important. The top 22 abundant proteins in plasma make up over 99% of the total protein mass, while low-abundance proteins account for less than 1%. Moreover, many potential tumor biomarkers have been mainly found in the low-abundance protein area.
Proteonano™ Kit v.s. Depletion
Instead of depletion, the Proteonano™ Low-Abundance Plasma Proteomics Kit directly enriches low-abundance proteins:
-
It prevents the loss of valuable protein information, preserves low-abundance proteins more effectively, and increases the number of proteins detected.
-
The kit outperforms traditional depletion methods, identifying around 4,000 proteins compared to about 1,000 with depletion.
Proteonano™ UltraPlex Proteomics Platform
The Proteonano™ Ultraplex Proteomics Platform, developed by Nanomics Biotechnology, is a highly automated and standardized system. It consists of the Proteonano™ Kit, Nanomics G1 workstation, and AI-powered proteomics analysis software, specifically addressing the bottlenecks in detecting low-abundance proteins in mass spectrometry-based proteomics.
Proteonano™ Kit series is composed of AI-designed polypeptides to selectively bind and enrich low abundant proteins in biofluid samples with picogram sensitivity and peptide-level specificity.
Features
Multiplex + Ultradepth
Detect 1,000-5,000 plasma proteins and biomarkers in a single run, spanning 9 orders of magnitude in abundance.
Unbiased Detection
Provides broad analysis of the entire proteome, including post-translational modifications, allelic variations, and alternative splicing.
High Throughput
Greatly simplify sample prep, allowing the workstation to process 100 samples per day per unit.
Seamless Integration
Seamlessly fits into existing LC-MS workflows, compatible with various LC-MS, and requires no extra large equipment.
